News Releases

SEATTLE --(BUSINESS WIRE)--Sep. 15, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the Oppenheimer Fall

SEATTLE --(BUSINESS WIRE)--Sep. 8, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the H.C.

- Signed option to license worldwide rights to ALPN-101 with AbbVie - - Received $60 million upfront cash payment from AbbVie; eligible to receive up to $805 million for exercise of the option and success-based development, regulatory and commercial milestones - - Dosed first patient in NEON-1

SEATTLE --(BUSINESS WIRE)--Aug. 5, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the 2020 Wedbush PacGrow

SEATTLE --(BUSINESS WIRE)--Aug. 4, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2020 financial

SEATTLE --(BUSINESS WIRE)--Jul. 24, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase

- ALPN-202 is a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor - SEATTLE --(BUSINESS WIRE)--Jun. 24, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and

- Alpine Immune Sciences grants AbbVie option to license worldwide rights to ALPN-101,   a phase 2-ready,   first-in-class dual CD28/ICOS costimulation antagonist, building on AbbVie’s commitment to developing novel therapies in Immunology - Alpine Immune Sciences to receive $60 million in an

SEATTLE --(BUSINESS WIRE)--Jun. 15, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases,   today announced the company will present a poster at the AACR Virtual